Synlogic
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | <1m | 1.8m | 1.2m | 3.4m | <1m | - | 22.8m |
| % growth | (75 %) | 222 % | (33 %) | 186 % | (92 %) | - | - |
| EBITDA | (60.5m) | (60.8m) | (63.6m) | (51.3m) | - | - | - |
| % EBITDA margin | (11095 %) | (3464 %) | (5392 %) | (1520 %) | - | - | - |
| Profit | (59.2m) | (60.6m) | (66.1m) | (57.3m) | (32.9m) | (5.7m) | (3.0m) |
| % profit margin | (10857 %) | (3453 %) | (5606 %) | (1699 %) | (12495 %) | - | (13 %) |
| EV / revenue | -46.2x | 18.3x | -20.4x | -3.7x | 1.6x | - | 0.3x |
| EV / EBITDA | 0.4x | -0.5x | 0.4x | 0.2x | - | - | - |
| R&D budget | 47.5m | 47.1m | 52.0m | 44.0m | - | - | - |
| R&D % of revenue | 8711 % | 2687 % | 4411 % | 1304 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$29.4m | Series A | ||
$5.0m | Series A | ||
| N/A | N/A | IPO | |
$40.0m | Series B | ||
$42.0m | Series C | ||
* | N/A | $50.0m | Post IPO Equity |
* | N/A | $30.0m | Post IPO Equity |
* | N/A | $50.0m | Post IPO Equity |
$80.0m | Post IPO Equity | ||
| N/A | $30.0m | Post IPO Equity | |
| N/A | $45.0m | Post IPO Equity | |
* | N/A | $21.0m | Post IPO Equity |
| Total Funding | AUD180m | ||
Related Content
Recent News about Synlogic
EditSynlogic, Inc. operates in the biotechnology sector, focusing on the development of synthetic biology-based therapeutics. The company engineers bacteria to perform specific functions within the human body, targeting complex diseases that are difficult to treat with traditional methods. Synlogic's primary clients include healthcare providers and pharmaceutical companies. The company operates in the global healthcare market, leveraging its proprietary technology to create novel treatments. Synlogic generates revenue through research and development partnerships, grants, and potential future product sales. Key products in development include SYNB1891, aimed at stimulating immune responses in challenging tumors.
Keywords: synthetic biology, bacterial therapeutics, complex diseases, immune response, healthcare, biotechnology, engineered bacteria, R&D partnerships, SYNB1891, pharmaceutical.